SCHEMBL1793176

SCHEMBL1793176

COC(=O)[C@H](Cc1ccccc1)NC(=O)c1ccccc1

nearest known ligand 0.76

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.76
RAB9A P51151 1/20 0.76
ALDH1A1 P00352 4/20 0.75
LMNA P02545 1/20 0.75
GLA P06280 1/20 0.75
CTSL P07711 3/20 0.70
ATM Q13315 2/20 0.65
THRB P10828 1/20 0.63
CYP2C9 P11712 1/20 0.63
CYP2C19 P33261 1/20 0.63
HSD17B10 Q99714 1/20 0.63
CTSS P25774 1/20 0.62
CTSK P43235 1/20 0.62
POLB P06746 1/20 0.62
ACE P12821 2/20 0.61
L3MBTL1 Q9Y468 1/20 0.58
TACR3 P29371 1/20 0.57
KDM4E B2RXH2 1/20 0.57
PKM P14618 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2461492 1.00 GAA (0.76) GAARAB9AALDH1A1LMNAGLA
SCHEMBL31206887 1.00 GAA (0.76) GAARAB9AALDH1A1LMNAGLA
SCHEMBL4369272 0.94 GAA (0.69) GAARAB9AALDH1A1LMNAGLA
SCHEMBL13669573 0.94 GAA (0.69) GAARAB9AALDH1A1LMNAGLA
SCHEMBL14733433 0.93 GAA (0.67) GAARAB9AALDH1A1LMNAGLA
SCHEMBL16515824 0.93 GAA (0.67) GAARAB9AALDH1A1LMNAGLA
SCHEMBL13525006 0.92 GAA (0.70) GAARAB9AALDH1A1LMNAGLA
SCHEMBL4175147 0.91 GAA (0.73) GAARAB9AALDH1A1LMNAGLA
SCHEMBL3928165 0.91 LNPEP (0.67) GAARAB9AALDH1A1LMNAGLA
SCHEMBL3928164 0.91 LNPEP (0.67) GAARAB9AALDH1A1LMNAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4684030-A2 METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP Martin-Luther-Universität Halle-Wittenberg (DE) 2026-01-28 EP disclosed
WO-2024227957-A2 METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP Martin-Luther-Universität Halle-Wittenberg (DE) 2024-11-07 WO disclosed
US-20230040081-A1 VACCINIA VIRAL POLYMERASE-MEDIATED VIRAL REPLICATION IMMUNOLUX INTERNATIONAL CORP. 2023-02-09 US disclosed
US-9243028-B2 Facile amide formation via S-nitroso thioacid intermediates WASHINGTON STATE UNIVERSITY (US) 2016-01-26 US disclosed
US-9243028-B2 Facile amide formation via S-nitroso thioacid intermediates WASHINGTON STATE UNIVERSITY (US) 2016-01-26 US disclosed
CN-102002063-B The dipeptide boronic acid that one class carboxylic acid and beta amino acids form and ester compound, preparation method and its usage JIANGSU SIMCERE PHARMACEUTICAL RESEARCH COMPANY LIMITED (CN) 2015-07-29 CN disclosed
EP-2141142-B1 METHOD FOR PRODUCING ALCOHOL BY HYDROGENATING LACTONE OR CARBOXYLIC ACID ESTER IN LIQUID PHASE TAKASAGO PERFUMERY CO LTD (JP) 2015-03-04 EP disclosed
CN-103721690-A N-ferrocenyl (benzoyl)-phenylalanine methyl ester bonded silica gel stationary phase as well as preparation method and application thereof UNIV ZHENGZHOU 2014-04-16 CN disclosed
CN-103721690-A N-ferrocenyl (benzoyl)-phenylalanine methyl ester bonded silica gel stationary phase as well as preparation method and application thereof UNIV ZHENGZHOU 2014-04-16 CN disclosed
EP-1840116-B1 PROCESS FOR PRODUCING OPTICALLY ACTIVE BETA-HYDROXY-ALPHA-AMINOCARBOXYLIC ACID DERIVATIVE NISSAN CHEMICAL IND LTD (JP) 2012-10-03 EP disclosed
US-5532395-A HYDROGENATION CATALYSTS ) E. I. DU PONT DE NEMOURS AND COMPANY (US) 1996-07-02 US disclosed
US-5386061-A Reacting a bis(primary phosphine in the presence of a strong base with a cyclic sulfate; cyclization E. I. DU PONT DE NEMOURS AND COMPANY (US) 1995-01-31 US disclosed
US-5329015-A Catalysts for stereospecific reactions E. I. DU PONT DE NEMOURS AND COMPANY (US) 1994-07-12 US disclosed
EP-0592552-A1 CHIRAL PHOSPHOLANES VIA CHIRAL 1,4-DIOL CYCLIC SULFATES. DU PONT (US) 1994-04-20 EP disclosed
WO-1993001199-A1 CHIRAL PHOSPHOLANES VIA CHIRAL 1,4-DIOL CYCLIC SULFATES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1993-01-21 WO disclosed
US-5171892-A Chiral phospholanes via chiral 1,4-diol cyclic sulfates E. I. DU PONT DE NEMOURS AND COMPANY (US) 1992-12-15 US disclosed
EP-0145265-B1 ALPHA-AMINO ACIDS THROUGH CATALYTIC REACTION OF CO AND A HYDROXYL COMPOUND WITH ENAMIDES THE STANDARD OIL COMPANY (US) 1989-09-20 EP disclosed
US-4749786-A α-amino acids through catalytic reaction of CO and a hydroxyl compound with enamides THE STANDARD OIL COMPANY (US) 1988-06-07 US disclosed
US-4710574-A HYDROCARBOXYLATION OF UNSATURATED AMIDES THE STANDARD OIL COMPANY (US) 1987-12-01 US disclosed
EP-0145265-A2 Alpha-amino acids through catalytic reaction of CO and a hydroxyl compound with enamides THE STANDARD OIL COMPANY (US) 1985-06-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230040081-A1 VACCINIA VIRAL POLYMERASE-MEDIATED VIRAL REPLICATION POLR1G, POLR1A, POLR1E GAA 2118/4885RAB9A 2866/4885ALDH1A1 4620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.